2880 DE AGUSTIN JA et al. Circ J 2018; 82: ORIGINAL ARTICLE doi: /circj.CJ Discongruence Index
|
|
- Delilah O’Brien’
- 5 years ago
- Views:
Transcription
1 2880 DE AGUSTIN JA et al. Circ J 2018; 82: ORIGINAL ARTICLE doi: /circj.CJ Valvular Heart Disease Discongruence Index Simple Indicator to Predict Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement Jose Alberto de Agustin, MD, PhD; Fabian Islas, MD; Pilar Jimenez-Quevedo, MD, PhD; Luis Nombela-Franco, MD, PhD; Andrea Rueda Liñares, MD; Patricia Mahia, MD, PhD; Pedro Marcos-Alberca, MD, PhD; Eduardo Pozo, MD, PhD; Jose Juan Gomez de Diego, MD, PhD; Maria Luaces, MD, PhD; Ivan-Javier Nuñez-Gil, MD, PhD; Miguel Ángel Garcia-Fernandez, MD, PhD; Antonio Fernandez-Ortiz, MD, PhD; Carlos Macaya, MD, PhD; Leopoldo Perez de Isla, MD, PhD Background: Prosthesis-patient mismatch (PPM) after transcatheter aortic valve replacement (TAVR) remains an important issue. The aim of this study was to assess the value of a new discongruence index, to predict PPM after TAVR. Methods and Results: A total of 185 patients with severe aortic stenosis who underwent TAVR with the Edwards Sapien prosthesis or CoreValve Revalving system were included (Edwards valve, n=119; Core Valve Revalving system, n=66). Discongruence index was calculated pre-procedurally as the ratio of selected transcatheter valve size (mm) to body surface area (cm 2 ). PPM was defined as effective orifice area (EOA) 0.85 cm 2 /m 2 on transthoracic echocardiography before hospital discharge. Mean age was 82±5 years and 72 patients (38.9%) were men. The overall incidence of post-tavr PPM was 35.1% (n=65). Discongruence index correlated with post-tavr indexed EOA (y= x; P<0.001). On multivariate logistic regression analysis, discongruence index was the only independent predictor of post-tavr PPM (OR, 0.15; 95% CI: ; P=0.012), and the area under the receiver operating characteristic curve was 0.62 (95% CI: , P=0.003), with an optimal cut-off point of (sensitivity, 86.2%; specificity, 72.5%; positive predictive value, 74.3%; negative predictive value, 83.4%). Conclusions: The new discongruence index may be useful tool to predict PPM after TAVR. Key Words: Discongruence index; Echocardiography; Prosthesis-patient mismatch; Transcatheter aortic valve replacement Transcatheter aortic valve replacement (TAVR) is an established therapeutic option for patients with aortic stenosis considered to be at high or prohibitive surgical risk. 1 3 Valve prosthesis-patient mismatch (PPM) occurs when the effective orifice area (EOA) of the prosthetic valve is too small relative to body size. 4,5 Its principal consequence is the presence of high gradients through correctly functioning valves. Despite a lower incidence of PPM after TAVR compared with surgical replacement, it is still an important problem because it affects morbi-mortality. 6 Thus, the implementation of preventive strategies to avoid post-tavr PPM is necessary, particularly in high-risk patients (i.e., those with large body surface area [BSA]) or those susceptible to the effect of PPM, such as in the case of severe left ventricular (LV) hypertrophy, reduced LV ejection fraction (LVEF), and paradoxi- cal low-flow severe aortic stenosis. 7 The currently available options for post-tavr PPM prevention, however, are limited, and it is crucial to carefully select prosthesis type and size. The aim of the current study was therefore to assess the value of a new discongruence index to predict PPM after TAVR. Methods Subjects From March 2012 to November 2016 we included consecutive patients with symptomatic severe aortic stenosis who had successfully undergone TAVR with balloon expandable Edwards Sapien XT prostheses (Edwards Lifesciences, Irvine, CA, USA) or CoreValve Revalving system (CRS, Medtronic, Minneapolis, MN, USA) at the Received March 12, 2018; revised manuscript received July 11, 2018; accepted July 17, 2018; released online August 23, 2018 Time for primary review: 65 days Cardiovascular Institute, San Carlos University Clinical Hospital, Madrid (J.A.d.A., F.I., P.J-Q., L.N.-F., P.M., P.M.-A., E.P., J.J.G.d.D., M.L., I.-J.N.-G., M.A.G.-F., A.F.-O., C.M., L.P.d.I.); Cardiovascular Department, Gomez Ulla Military Hospital, Madrid (A.R.L.), Spain Mailing address: Jose Alberto de Agustín, MD, PhD, Cardiovascular Institute, Hospital Clinico Universitario San Carlos, Calle del Prof. Martin Lagos s/n, Madrid 28040, Spain. albertutor@hotmail.com ISSN All rights are reserved to the Japanese Circulation Society. For permissions, please cj@j-circ.or.jp
2 Discongruence Index to Predict Mismatch 2881 Table 1. Subject Clinical Characteristics vs. PPM After TAVR Clinical characteristics Overall (n=185) No PPM (n=120) PPM (n=65) P-value Age (years) 82.5± ±5 83.1± Gender (male) 72 (38.9) 47 (39.2) 25 (38.5) 0.92 Weight (kg) 71.3± ± ± Height (cm) 160.2± ±9 161± BSA (m 2 ) 1.74± ± ± BMI (kg/m 2 ) 27.8± ± ± Logistic EuroSCORE 17.1± ± ± Previous CAD 82 (44.3) 50 (41.7) 32 (49.2) 0.32 Hypertension 151 (81.6) 94 (78.3) 57 (87.7) 0.11 Hypercholesterolemia 110 (59.5) 72 (60.0) 38 (58.5) 0.83 Diabetes 56 (30.3) 39 (32.5) 17 (26.2) 0.37 Smoking 39 (21.1) 26 (21.7) 13 (20.0) 0.79 AF 61 (33.0) 40 (33.3) 21 (32.3) 0.88 Data given as mean ± SD or n (%). AF, atrial fibrillation; BMI, body mass index; BSA, body surface area; CAD, coronary artery disease; EuroSCORE, European System for Cardiac Operative Risk Evaluation score; PPM, prosthesispatient mismatch; TAVR, transcatheter aortic valve replacement. Statistical Analysis Continuous variables are expressed as mean ± SD. Categorical variables are presented as absolute number or percentage. For continuous variables, significant differences between groups were analyzed using Student s t-test. Chi-squared test (when all expected cell counts were >5) or Fisher s exact test (when any expected cell count was <5) was used to assess the differences in categorical variables. Linear regression analysis was used to assess the relationpresent center. Patients with severe symptomatic aortic stenosis were considered as candidates for TAVR if they had a logistic European System for Cardiac Operative Risk Evaluation score (EuroSCORE) >20%; if surgery was deemed to be of excessive risk due to significant comorbidities; or if other risk factors not captured by these scoring systems (e.g., porcelain aorta) were present. Eligibility for TAVR was established on the consensus of a local multidisciplinary heart team, including clinical cardiologists, interventional cardiologists and cardiac surgeons. An exclusion criterion was inadequate echocardiographic acoustic apical window. The new discongruence index was defined as selected transcatheter valve size (mm)/bsa (cm 2 ). Transcatheter valve size refers to the external dimension from the manufacturer, not the internal geometric orifice area. BSA was calculated using the DuBois formula (BSA [cm 2 ]=weight [kg] height [cm] ). The initial full sample consisted of 196 patients. Five patients were excluded because they did not undergo postoperative echocardiogram, and 6 due to the presence of poor acoustic window, resulting in a final sample of 185 patients. Transfemoral access was used in all patients. All patients gave written informed consent according to the approved protocol by the institutional review board. Echocardiography Transthoracic echocardiography was performed at baseline and before discharge by experienced sonographers using a commercially available ultrasound machine (ie33; Philips Healthcare, Amsterdam, The Netherlands; and Artida; Toshiba Medical Systems, Tokyo, Japan). A complete 2-D, color, pulsed and continuous-wave Doppler echocardiogram was performed according to the current guidelines. 8 The severity of aortic stenosis was evaluated using the EOA obtained with the continuity equation, and the mean aortic gradient. 9 LV volumes and EF were obtained using the Simpson biplane method. Specifically, all echocardiographic measurements were averaged from 5 consecutive beats in patients with atrial fibrillation. All echocardiographic parameters were calculated offline using Xcelera (Philips Health Care, Andover, MA, USA). All procedures were monitored on intraprocedural 3-D transesophageal echocardiography using an ie33 ultrasound system with a fully sampled matrix array transducer (X7-2t Live 3-D transducer, Philips Medical Systems, Andover, MA, USA). The prosthesis size was selected according to the average annulus diameter, area and perimeter, which were measured systematically on multislice computed tomography. 10 These measurements were performed in compliance with currently available recommendations Post-TAVR paravalvular aortic regurgitation (AR) was evaluated using color Doppler and graded as mild (1/4), mild-moderate (2/4), moderate-severe (3/4) or severe (4/4) according to the sum of the cross-sectional vena contracta area on short-axis view. An integrative, semiquantitative approach was used to assess the severity of central, paravalvular, and total regurgitation. 14 Definition of Post-TAVR PPM The presence of PPM was assessed before hospital discharge. The aortic annulus measurement was performed in parasternal long-axis view. 14 The diameter of the LV outflow tract (LVOT) was measured 5 10 mm from the aortic annulus in mid-systole. For LVOT measurements, pulsedwave Doppler was used, and for transaortic measurements continuous-wave Doppler was used. The EOA was obtained from the continuity equation, and it was indexed to BSA. In patients with atrial fibrillation, 5 measurements were averaged. For the analysis, patients were divided into 2 groups according to the presence of PPM. PPM severity was graded using the indexed EOA, defining moderate as 0.65 and 0.85 cm 2 /m 2, and severe as <0.65 cm 2 /m 2. 15
3 2882 DE AGUSTIN JA et al. Figure 1. Linear regression plot of discongruence index vs. post-transcatheter aortic valve replacement (post-tavr) indexed effective orifice area (EOA). ship between 2 continuous variables. Univariate and multivariate logistic regression analysis was performed to determine predictors of post-tavr PPM. Receiver operating characteristic (ROC) curves were used to determine the predictive value of the different parameters. Box plots were created to illustrate the distribution of the post-tavr indexed EOA in the 3 groups (no, moderate, or severe PPM). Differences were accepted as statistically significant at P<0.05. SPSS 18.0 (SPSS, Chicago, IL, USA) was used for the statistical analysis. Results Patient Data One hundred and eighty-five consecutive patients who received the Edwards valve (n=119) or the CoreValve Revalving system (n=66) by transfemoral approach at the present institution were included. Patient clinical baseline characteristics are listed in Table 1. Mean age was 82±5 years and 72 patients (38.9%) were men. Median EOA at baseline was 0.61±0.17 cm 2 (indexed, 0.35±0.08 cm 2 /m 2 ) and mean gradient was 49±19 mmhg. Mean aortic annulus diameter was 2.2±0.25 cm. Mean EF was 56±17%. A 23-mm prosthesis was used in 127 patients (68.6%); a 26-mm prosthesis in 36 (19.5%); a 29-mm prosthesis in 20 (10.8%); and a 31-mm prosthesis in 2 (1.1%). As expected, TAVR produced a significant improvement in EOA (1.7±0.45 cm 2, P<0.001), indexed EOA (0.99±0.28 cm 2 /m 2, P<0.001), and mean transaortic gradient (9.3±4.5 mmhg, P<0.001). On linear regression analysis, discongruence index correlated with post-tavr indexed EOA (y= x; P<0.001; Figure 1). After TAVR, there was a significant improvement in LVEF (from 56±17 to 63±11%, P<0.001). No AR was seen in 80 patients (43.2%); mild AR (1/4) in 51 (27.6%); mild-moderate AR (2/4) in 39 (21.1%); and moderate-severe AR (3/4) in 7 (3.8%). Severe AR (4/4) was not seen. Post-TAVR PPM The overall incidence of post-tavr PPM was 35.1% (n=65), assessed before hospital discharge. Moderate PPM (indexed EOA cm 2 /m 2 ) was present in 54 patients (29.2%), and severe PPM (indexed EOA <0.65 cm 2 /m 2 ) was seen in 11 patients (5.9%; Figure 2). Table 1 lists the baseline clinical characteristics according to PPM status. Larger body weight, BSA and body mass index (BMI) were associated with a higher incidence of PPM. Table 2 lists echocardiographic characteristics at baseline and post-tavr according to PPM status. Patients with PPM had a significantly lower discongruence index (13.5±1.5 vs. 14.3±1.8, P=0.002). Nevertheless, there were no statistically significant differences in other variables, including valve type, prosthesis size, native annulus diameter, EOA, gradient, EF, or the presence of bulky calcifications. As expected, after TAVR, patients with PPM had a significantly higher peak gradient (21.80±11.4 vs ±5.8, P<0.001), mean gradient (5.7±0.71 vs. 3.2±0.29, P<0.001), and lower EOA (1.3±0.17 vs.1.9±0.40, P<0.001), and indexed EOA (0.72±0.07 vs. 1.14±0.25, P<0.001). Significant improvement in LVEF was noted after TAVR between patients with and without PPM but this was not significant (2.71±14.4% vs. 5.62±16.6%, P=0.26). Table 3 lists the univariate and multivariate predictors of post-tavr PPM. On univariate analysis BSA (OR, 13.5; 95% CI: ; P=0.02), body weight (OR, 1.04; 95% CI: ; P=0.03), BMI (OR, 1.09; 95% CI: ; P=0.04), baseline mean gradient (OR, 0.97; 95% CI: ; P=0.02), interventricular septum thickness (OR, 1.25; 95% CI: ; P=0.049), and discongruence index (OR, 0.75; 95% CI: ; P=0.004) were significantly associated with post-tavr AR. Multivariate logistic regression analysis was carried out including the following variables: BSA, baseline mean gradient, predilatation, interventricular septum thickness, baseline EF, and discongruence index. On this multivariate logistic regression analysis only discongruence index was an independent predictor of post-tavr
4 Discongruence Index to Predict Mismatch 2883 Figure 2. Distribution of prosthesispatient mismatch (PPM) after transcatheter aortic valve replacement according to indexed effective orifice area (EOA). The box for each group represents IQR (25 75th percentile) and the line in the box is the median. Bottom and top whiskers indicate the 10th and 90th percentiles, respectively. Table 2. Echocardiography Characteristics vs. PPM After TAVR Overall (n=185) No PPM (n=120) PPM (n=65) P-value Baseline Peak gradient (mmhg) 81.4± ± ± Mean gradient (mmhg) 49±1 50±7 45± EOA (cm 2 ) 0.61± ± ± Indexed EOA (cm 2 /m 2 ) 0.35± ± ± Aortic annulus diameter (cm) 2.2± ± ± Large calcifications (>5 mm) 44 (23.8) 26 (33.8) 18 (35.3) 0.85 IVS thickness (mm) 15.5± ± ± Indexed LVM (g/m 2 ) 148.7± ± ± LVEF (%) 56±17 57±14 61± After TAVR Peak gradient (mmhg) 17.8± ± ±11.4 <0.001 Mean gradient (mmhg) 9.3± ± ±0.71 <0.001 EOA (cm 2 ) 1.7± ± ±0.17 <0.001 Indexed EOA (cm 2 /m 2 ) 0.99± ± ±0.07 <0.001 LVEF (%) 62.9± ± ±9 0.5 Prosthesis size (mm) 24.3± ± ± Prosthesis type (Edwards) 119 (64.3) 74 (61.6) 45 (69.2) 0.57 Discongruence index 14.1± ± ± Data given as mean ± SD or n (%). EOA, effective orifice area; IVS, interventricular septum; LVEF, left ventricular ejection fraction; LVM, left ventricular mass. Other abbreviaions as in Table 1. PPM (OR, 0.15; 95% CI: ; P=0.012). The area under the ROC curve for discongruence index (Figure 3) was 0.62 (95% CI: , P=0.003), with an optimal cut-off point of (sensitivity, 86.2%; specificity, 72.5%; positive predictive value, 74.3%; negative predictive value, 83.4%) to predict post-tavr PPM. Discussion This study demonstrates that a simple index (discongruence index) is the best parameter to predict post-tavr PPM. As far as we know, this subject has never been studied before. In the present study PPM was relatively common, occurring moderately in 29.2% and severely in 5.9% of the TAVR patients. These data are similar to those in
5 2884 DE AGUSTIN JA et al. Table 3. Predictors of Post-TAVR PPM OR 95% CI P-value Univariate logistic regression analysis Age (years) Weight (kg) Height (cm) BSA (m 2 ) BMI (kg/m 2 ) Aortic annulus diameter (cm) Baseline mean gradient (mmhg) Baseline EOA (cm 2 ) Large calcifications (>5 mm) Predilatation IVS thickness (mm) Indexed LVM (g/m 2 ) Baseline LVEF (%) Prosthesis size (mm) Prosthesis type Discongruence index Multivariate logistic regression analysis BSA (m 2 ) Baseline mean gradient (mmhg) Predilatation IVS thickness (mm) Baseline LVEF (%) Discongruence index Abbreviaions as in Tables 1,2. Figure 3. Receiver operating characteristic curve for prediction of post-transcatheter aortic valve replacement prosthesispatient mismatch using the discongruence index. previous studies, ranging from 22% to 40%, and are slightly lower than after conventional open aortic valve replacement Thus, PPM remains an important issue in the TAVR era and preventive strategies are needed, particularly in patients at high risk. Discongruence index corre- lated with post-tavr indexed EOA, and the proposed cut-off point (15.02) had a high sensitivity (86.2%) to predict post-tavr PPM. Taking this new index into consideration, prevention of PPM may be possible with the selection of larger transcatheter valve sizes in patients with discongruence index <15. TAVR is now a widely accepted intervention for patients with severe aortic stenosis who are deemed to have prohibitive or high surgical risk, and it is included as such in the American and European treatment guidelines. 1 3 Optimization of patient selection and device implantation, however, is imperative to improve prognosis. Echocardiography plays an important role in measuring aortic annulus dimension in patients undergoing TAVR. This is important because it determines both eligibility for TAVR and selection of prosthesis type and size, and can be potentially important in preventing PPM. Generally, to minimize PPM and paravalvular regurgitation, it is suggested that the transcatheter valve be slightly larger than the aortic annulus. PPM was first described by Rahimtoola in 1978, 4 and occurs when the prosthetic valve is too small relative to the patient s body size, causing a high transvalvular pressure gradient through a normally functioning prosthetic valve. PPM is defined as severe when the indexed EOA is <0.65 cm 2 /m 2 and moderate for indexed EOA cm 2 /m After conventional surgery, PPM has been described to range from 20% to 70%, being severe in 2 28% of patients Some patient characteristics have been shown to have a higher risk of PPM, such as advanced age, larger body size and aortic valve stenosis as the predominant lesion. 19 Although the influence of PPM on
6 Discongruence Index to Predict Mismatch 2885 short- and long-term survival is still controversial, there is considerable evidence that severe PPM has a detrimental effect on outcome Compared with surgical aortic valve replacement, TAVR has better hemodynamic performance, associated with a reduction in PPM. 6,15,23,24 On randomized comparison of patients from the PARTNER trial A cohort, TAVR was associated with lower prevalence of PPM (46% vs. 60%) and of severe PPM (20% vs. 28%), compared with surgical aortic valve replacement. 6 The difference in severe PPM was particularly important in patients with small aortic annuli (<20 mm). 6,25 The lower incidence of PPM in the TAVR series compared with the surgical series may be partly explained by the distention of the aortic annulus, the absence of a sewing ring, and a thinner transcatheter stent frame, causing less obstruction to blood flow. Furthermore, surgical prosthesis size is usually smaller than that of TAVR prostheses. The Edwards SAPIEN valve is currently available in 20, 23, 26, and 29 mm. The CoreValve device is available in 23, 26, 29, and 31 mm. For surgical aortic valve replacement, prostheses of 19 or 21 mm are available, and the incidence of PPM increases with smaller prosthesis size. 23,26 Some authors suggest that TAVR may be contemplated in patients with a small aortic annulus, given that these patients have increased risk of PPM after surgical aortic valve replacement. 6,25 Despite a lower incidence, the concern about the occurrence of PPM after TAVR remains an important problem. A recent analysis from the PARTNER trial supported the relationship between severe PPM and increased mortality, 6 pointing to the need to implement preventive strategies to avoid post-tavr PPM. 7 The currently available options for post-tavr PPM prevention, however, are limited. With regard to TAVR, when additional surgical procedures (e.g., aortic root enlargement) are not available, it is crucial to carefully select the patients, prosthesis type and size. To avoid the occurrence of PPM, selection of larger prosthesis size and the improvement of valve design are needed. Nevertheless, excessive oversizing has to be balanced against the risk of aortic rupture. The current study has demonstrated that the new and easy-to-calculate discongruence index may be useful in the selection of appropriate prosthesis size, preventing PPM after TAVR. Study Limitations Some limitations of the present study must be mentioned. This was a retrospective, descriptive study in a single center. We included recipients of the Edwards valve or the CoreValve because this cohort reflected our clinical experience. The cut-off value and the diagnostic accuracy of the discongruence index in the prediction of PPM could differ depending on the type of valve used. This, however, was not the main purpose of this study, and the statistical power was not high enough to demonstrate that difference due to the limited cohort size. We think that this issue should be better explored in future studies that specifically analyze the differences between these 2 types of valves. A larger patient group might have improved the strength of the present study. Early echocardiography after a significant intervention may skew hemodynamic results due to a hyperdynamic state. It would be expected, however, that the stent frame dimensions and hemodynamics have stabilized before discharge. Furthermore, later echocardiography introduces the added confounder of potential valve deterioration. This study lacked clinical evaluation of the post-tavr outcomes and the association with PPM. Conclusions Despite a lower incidence, PPM is relatively common in the TAVR era and it remains an important issue. Preventive strategies to avoid post-tavr PPM are needed, particularly in patients at high risk. The new discongruence index may be a useful tool to predict PPM after TAVR. Preventing the occurrence of PPM after TAVR may be possible with the selection of larger valve sizes, taking this new index into consideration. Disclosures The authors declare no conflicts of interest. References 1. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364: Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374: Rahimtoola SH. The problem of valve prosthesis-patient mismatch. Circulation 1978; 58: Dumesnil JG, Honos GN, Lemieux M, Beauchemin J. Validation and applications of indexed aortic prosthetic valve areas calculated by Doppler echocardiography. J Am Coll Cardiol 1990; 16: Pibarot P, Weissman NJ, Stewart WJ, Hahn RT, Lindman BR, McAndrew T, et al. Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: A PARTNER trial cohort-a analysis. J Am Coll Cardiol 2014; 64: Mohty D, Boulogne C, Magne J, Pibarot P, Echahidi N, Cornu E, et al. Prevalence and long-term outcome of aortic prosthesispatient mismatch in patients with paradoxical low-flow severe aortic stenosis. Circulation 2014; 130: S25 S Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: Burwash IG, Thomas DD, Sadahiro M, Pearlman AS, Verrier ED, Thomas R, et al. Dependence of Gorlin formula and continuity equation valve areas on transvalvular volume flow rate in valvular aortic stenosis. Circulation 1994; 89: Blanke P, Siepe M, Reinohl J, Zehender M, Beyersdorf F, Schlensak C, et al. Assessment of aortic annulus dimensions for Edwards SAPIEN Transapical Heart Valve implantation by computed tomography: Calculating average diameter using a virtual ring method. Eur J Cardiothorac Surg 2010; 38: Zamorano JL, Badano LP, Bruce C, Chan KL, Goncalves A, Hahn RT, et al. EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. Eur Heart J 2011; 32: Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: Messika-Zeitoun D, Serfaty JM, Brochet E, Ducrocq G, Lepage L, Detaint D, et al. Multimodal assessment of the aortic annulus diameter: Implications for transcatheter aortic valve implantation. J Am Coll Cardiol 2010; 55: Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener
7 2886 DE AGUSTIN JA et al. JS, Grayburn PA, et al. Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound: A report from the American Society of Echocardiography s Guidelines and Standards Committee and the Task Force on Prosthetic Valves. J Am Soc Echocardiogr 2009; 22: Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: Definition, clinical impact, and prevention. Heart 2006; 92: Mohty D, Malouf JF, Girard SE, Schaff HV, Grill DE, Enriquez- Sarano ME, et al. Impact of prosthesis-patient mismatch on long-term survival in patients with small St Jude Medical mechanical prostheses in the aortic position. Circulation 2006; 113: Florath I, Albert A, Rosendahl U, Ennker IC, Ennker J. Impact of valve prosthesis-patient mismatch estimated by echocardiographic determined effective orifice area on long-term outcome after aortic valve replacement. Am Heart J 2008; 155: Hahn RT, Pibarot P, Stewart WJ, Weissman NJ, Gopalakrishnan D, Keane MG, et al. Comparison of transcatheter and surgical aortic valve replacement in severe aortic stenosis: A longitudinal study of echocardiography parameters in cohort A of the PARTNER trial (placement of aortic transcatheter valves). J Am Coll Cardiol 2013; 61: Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis patient mismatch in the aortic valve position and its prevention. J Am Coll Cardiol 2000; 36: Blais C, Dumesnil JG, Baillot R, Simard S, Doyle D, Pibarot P. Impact of valve prosthesis-patient mismatch on short-term mortality after aortic valve replacement. Circulation 2003; 108: Bleiziffer S, Ali A, Hettich IM, Akdere D, Laubender RP, Ruzicka D, et al. Impact of the indexed effective orifice area on mid-term cardiac-related mortality after aortic valve replacement. Heart 2010; 96: Mohty D, Dumesnil JG, Echahidi N, Mathieu P, Dagenais F, Voisine P, et al. Impact of prosthesis-patient mismatch on longterm survival after aortic valve replacement: Influence of age, obesity, and left ventricular dysfunction. J Am Coll Cardiol 2009; 53: Clavel MA, Webb JG, Pibarot P, Altwegg L, Dumont E, Thompson C, et al. Comparison of the hemodynamic performance of percutaneous and surgical bioprostheses for the treatment of severe aortic stenosis. J Am Coll Cardiol 2009; 53: Kalavrouziotis D, Rodes-Cabau J, Bagur R, Doyle D, De Larochelliere R, Pibarot P, et al. Transcatheter aortic valve implantation in patients with severe aortic stenosis and small aortic annulus. J Am Coll Cardiol 2011; 58: Rodes-Cabau J, Pibarot P, Suri RM, Kodali S, Thourani VH, Szeto WY, et al. Impact of aortic annulus size on valve hemodynamics and clinical outcomes after transcatheter and surgical aortic valve replacement: Insights from the PARTNER Trial. Circ Cardiovasc Interv 2014; 7: Lopez S, Mathieu P, Pibarot P, Mohammadi S, Dagenais F, Voisine P, et al. Does the use of stentless aortic valves in a subcoronary position prevent patient-prosthesis mismatch for small aortic annulus? J Card Surg 2008; 23:
Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationReverse left atrium and left ventricle remodeling after aortic valve interventions
Reverse left atrium and left ventricle remodeling after aortic valve interventions Alexandra Gonçalves, Cristina Gavina, Carlos Almeria, Pedro Marcos-Alberca, Gisela Feltes, Rosanna Hernández-Antolín,
More informationTranscatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis and Small Aortic Annulus
Journal of the American College of Cardiology Vol. 58, No. 10, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.026
More informationSuccessful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement
Advanced Studies in Medical Sciences, Vol. 2, 2014, no. 1, 37-45 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/asms.2014.31213 Successful Transfemoral Edwards Sapien Aortic Valve Implantation
More informationNew Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology
New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor Cardiothoracic Radiology Disclosure I have no disclosure pertinent to this presentation.
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationTAVR: Echo Measurements Pre, Post And Intra Procedure
2017 ASE Florida, Orlando, FL October 10, 2017 8:00 8:25 AM 25 min TAVR: Echo Measurements Pre, Post And Intra Procedure Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationAS with reduced LV ejection fraction: Contractile reserve should be systematically assessed: PRO
AS with reduced LV ejection fraction: Contractile reserve should be systematically assessed: PRO Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Potential conflicts of interest
More informationPatient/prosthesis mismatch: how to evaluate and when to act?
Patient/prosthesis mismatch: how to evaluate and when to act? Svend Aakhus, MD, PhD Oslo University Hospital, Norway Disclosures: No conflict of interest Types of aortic valve prostheses (AVR) Mechanical
More informationProsthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators
More informationTrend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience
Cardiol Ther (2018) 7:191 196 https://doi.org/10.1007/s40119-018-0115-0 BRIEF REPORT Trend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience Anthony A. Bavry.
More informationComments restricted to Sapien and Corevalve 9/12/2016. Disclosures: Core Lab contracts with Edwards Lifesciences, Middlepeak, Medtronic
Para-ValvularRegurgitation post TAVR: Predict, Prevent, Quantitate, Manage Linda D. Gillam, MD, MPH, FACC, FASE Chair, Department of Cardiovascular Medicine Morristown Medical Center/Atlantic Health System
More informationManagement of Difficult Aortic Root, Old and New solutions
Management of Difficult Aortic Root, Old and New solutions Hani K. Najm MD, Msc, FRCSC,, FACC, FESC Chairman, Pediatric and Congenital Heart Surgery Cleveland Clinic Conflict of Interest None Difficult
More informationTAVR in 2017 What we know? What to expect?
Journal of Geriatric Cardiology (2018) 15: 55 60 2018 JGC All rights reserved; www.jgc301.com Perspective Open Access TAVR in 2017 What we know? What to expect? Panagiota Kourkoveli 1,*, Konstantinos Spargias
More informationAortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
More informationTranscatheter Aortic Valve Implantation in Patients With Concomitant Mitral and Tricuspid Regurgitation
Transcatheter Aortic Valve Implantation in Patients With Concomitant Mitral and Tricuspid Regurgitation Andrea Hutter, MD, Sabine Bleiziffer, MD, PhD, Valerie Richter, MS, Anke Opitz, MD, Ina Hettich,
More informationOptimal Imaging Technique Prior to TAVI -Echocardiography-
2014 KSC meeting Optimal Imaging Technique Prior to TAVI -Echocardiography- Geu-Ru Hong, M.D. Ph D Associate Professor of Medicine Division of Cardiology, Severance Cardiovascular Hospital Yonsei University
More informationClinical predictors of prosthesis-patient mismatch after aortic valve replacement for aortic stenosis
CLINICS 2012;67(1):55-60 DOI:10.6061/clinics/2012(01)09 CLINICAL SCIENCE Clinical predictors of prosthesis-patient mismatch after aortic valve replacement for aortic stenosis Luis M. Astudillo, I Orlando
More informationThe impact of prosthesis patient mismatch after aortic valve replacement varies according to age at operation
Editor s choice Scan to access more free content 1 Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, Maryland, USA 2 Division of Cardiac Surgery, University of Ottawa Heart Institute,
More informationAppropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y.
Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y. Szeto, MD on behalf of The PARTNER Trial Investigators and The PARTNER
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationHow to Avoid Prosthesis-Patient Mismatch
How to Avoid Prosthesis-Patient Mismatch Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE, FESC Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC
More informationIncidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation
Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation Ömer Aktug 1, MD; Guido Dohmen 2, MD; Kathrin Brehmer 1, MD; Verena Deserno 1 ; Ralf Herpertz 1 ; Rüdiger
More informationProsthesis-Patient Mismatch or Prosthetic Valve Stenosis?
EuroValves 2015, Nice Prosthesis-Patient Mismatch or Prosthetic Valve Stenosis? Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE FESC Canada Research Chair in Valvular Heart Diseases Université LAVAL Disclosure
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationOutcomes After Transcatheter Aortic Valve Implantation: Transfemoral Versus Transapical Approach
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationValve prosthesis-patient mismatch (PPM) was first defined
Impact of Valve Prosthesis-Patient Mismatch on Short-Term Mortality After Aortic Valve Replacement Claudia Blais, BSc; Jean G. Dumesnil, MD; Richard Baillot, MD; Serge Simard, MS; Daniel Doyle, MD; Philippe
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationMinimalist Transcatheter Aortic Valve Replacement (MA-TAVR)
Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR) Jensen HA, Condado JF, Devireddy C, Binongo JN, Leshnower BG, Babaliaros V, Sarin EL, Lerakis S, Guyton RA, Stewart JP, Syed AQ, Mavromatis K,
More informationDoppler echocardiography is currently the
Doppler Echocardiography of 119 Normal-functioning St Jude Medical Mitral Valve Prostheses: A Comprehensive Assessment Including Time-velocity Integral Ratio and Prosthesis Performance Index* Joseph F.
More informationHow Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, 2016 11:00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D
More informationQUANTIFICATION AND PREVENTION TECHNIQUES OF PROSTHESIS-PATIENT MISMATCH
QUANTIFICATION AND PREVENTION TECHNIQUES OF PROSTHESIS-PATIENT MISMATCH 1,2 Radu A. SASCĂU 3 Cristina OLARIU 1,2 Cristian STĂTESCU 1 Internal Medicine Department, Gr.T.Popa University of Medicine and Pharmacy,
More informationTranscatheter Aortic Valve Replacement
Journal of the American College of Cardiology Vol. 59, No. 23, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2012.02.020
More informationOutcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison
Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Mauri, V. et al.: Circ Cardiovasc Interv. 2017;10:e005013 All trademarks are the property
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38522 holds various files of this Leiden University dissertation. Author: Ewe, See Hooi Title: Aortic valve disease : novel imaging insights from diagnosis
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationTranscatheter valve-in-valve implantation for degenerated surgical bioprostheses
Review Article Transcatheter valve-in-valve implantation for degenerated surgical bioprostheses Dale J. Murdoch, John G. Webb Centre for Heart Valve Innovation, St. Paul s Hospital, Vancouver, Canada Contributions:
More informationPPM: How to fit a big valve in a small heart
PPM: How to fit a big valve in a small heart Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC King Abdulaziz Cardiac Centre National Guard Health Affairs Riyadh, Saudi Arabia GHA meeting Muscat
More informationImaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013
Imaging in TAVI Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston Scientific, St Jude, BMS imaging, GE Healthcare,
More informationProf. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM
The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?
More informationCopyright by ICR Publishers 2014
Comprehensive Hemodynamic Performance and Frequency of Patient-Prosthesis Mismatch of the St. Jude Medical Trifecta Bioprosthetic Aortic Valve Ajay Yadlapati 1, Jimmy Diep 3, Mary-Jo Barnes 2, Tristan
More informationJournal of the American College of Cardiology Vol. 44, No. 9, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, 9, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.04.062 Relation
More informationImpact of Prosthesis-Patient Mismatch on Long-Term Survival After Aortic Valve Replacement
Journal of the American College of Cardiology Vol. 53, No. 1, 9 9 by the American College of Cardiology Foundation ISSN 735-197/9/$36. Published by Elsevier Inc. doi:1.116/j.jacc.8.9.22 Valvular Heart
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationAortic Stenosis: an Overview. Clinical Evaluation, Guidelines and Treatment: from Surgery to Current Indications for TAVI
Aortic Stenosis: an Overview Guidelines and Treatment: from Surgery to Current Aortic Stenosis Aortic stenosis (AS) is a life-threatening valvular heart disease, most commonly occurring in elderly patients
More informationAortic Valve Stenosis: When stress TTE and/or TEE is required to make the diagnosis and guide treatment
Aortic Valve Stenosis: When stress TTE and/or TEE is required to make the diagnosis and guide treatment Stefanos Karagiannis MD PhD Cardiologist Director Echocardiology Dpt Athens Medical Center ESC 2017
More informationProsthetic valve dysfunction: stenosis or regurgitation
Prosthetic valve dysfunction: stenosis or regurgitation Jean G. Dumesnil MD, FRCP(C), FACC, FASE(Hon) Quebec Heart and Lung Institute, Québec, Québec No disclosures Possible Causes of High Gradients in
More information«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer
«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer Philippe Pibarot, DVM, PhD, FACC, FAHA, FESC, FASE Canada Research Chair in Valvular Heart Diseases Université LAVAL
More informationPARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
O P E N A C C E S S Department of Cardiology, Aswan Heart Centre *Email: ahmed.elguindy@aswanheartcentre.com Lessons from the trials PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients Ahmed ElGuindy*
More informationEchocardiography: Guidelines for Valve Quantification
Echocardiography: Guidelines for Echocardiography: Guidelines for Chamber Quantification British Society of Echocardiography Education Committee Richard Steeds (Chair), Gill Wharton (Lead Author), Jane
More informationIncidence of prosthesis-patient mismatch in patients receiving mitral Biocor porcine prosthetic valves
INTERVENTION/VALVULAR HEART DISEASE ORIGINAL ARTICLE Cardiology Journal 2016, Vol. 23, No. 2, 178 183 DOI: 10.5603/CJ.a2016.0011 Copyright 2016 Via Medica ISSN 1897 5593 Incidence of prosthesis-patient
More informationNew imaging modalities for assessment of TAVI procedure and results. R Dulgheru, MD Heart Valve Clinic CHU, Liege
New imaging modalities for assessment of TAVI procedure and results R Dulgheru, MD Heart Valve Clinic CHU, Liege Disclosure of Interest I, Raluca Dulgheru, DO NOT HAVE a financial interest/arrangement
More informationMild paravalvular regurgitation is not an independent predictor of mortality following TAVI
Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38522 holds various files of this Leiden University dissertation. Author: Ewe, See Hooi Title: Aortic valve disease : novel imaging insights from diagnosis
More informationLow Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor
Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University
More informationRole of Transesophageal Echocardiography in the Diagnosis of Paradoxical Low Flow, Low Gradient Severe Aortic Stenosis
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Role of Transesophageal Echocardiography in the Diagnosis of Paradoxical Low Flow, Low Gradient Severe Aortic Stenosis
More informationEstablishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS
Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T H E P A R T N E R T R
More informationAortic stenosis (AS) is common with the aging population.
New Insights Into the Progression of Aortic Stenosis Implications for Secondary Prevention Sanjeev Palta, MD; Anita M. Pai, MD; Kanwaljit S. Gill, MD; Ramdas G. Pai, MD Background The risk factors affecting
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationAortic valve replacement and prosthesis-patient mismatch in the era of trans-catheter aortic valve implantation
Gen Thorac Cardiovasc Surg (2016) 64:435 440 DOI 10.1007/s11748-016-0657-9 CURRENT TOPICS REVIEW ARTICLE Aortic valve replacement and prosthesis-patient mismatch in the era of trans-catheter aortic valve
More informationRANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING
AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND
More informationLow Gradient Severe? AS
Low Gradient Severe? AS Philippe Pibarot, DVM, PhD, FACC, FAHA, FESC, FASE Canada Research Chair in Valvular Heart Diseases Institut Universitaire de Cardiologie et de Pneumologie de Québec / Québec Heart
More informationPortico (St. Jude Medical Inc, St.
Review Article Portico Transcatheter Heart Valve Apostolos Tzikas 1,2, Michael Chrissoheris 2, Antonios Halapas 2, Konstantinos Spargias 2 1 Interbalkan European Medical Centre, Thessaloniki, 2 Hygeia
More informationImpact of age on transcatheter aortic valve implantation outcomes: a comparison of patients aged 80 years versus patients > 80 years
Journal of Geriatric Cardiology (2016) 13: 31 36 2016 JGC All rights reserved; www.jgc301.com Research Article Open Access Impact of age on transcatheter aortic valve implantation outcomes: a comparison
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationComprehensive Echo Assessment of Aortic Stenosis
Comprehensive Echo Assessment of Aortic Stenosis Smonporn Boonyaratavej, MD, MSc King Chulalongkorn Memorial Hospital Bangkok, Thailand Management of Valvular AS Medical and interventional approaches to
More informationPost-TAVI Cerebral Embolisms and Potential Protection Means
Post-TAVI Cerebral Embolisms and Potential Protection Means Josep Rodés-Cabau, MD Quebec Heart & Lung Institute, Laval University Quebec City, Quebec, Canada EBR Marseille, May 2012 Conflict of Interest
More informationEchocardiographic Evaluation of Mitral Valve Prostheses
Echocardiographic Evaluation of Mitral Valve Prostheses Dennis A. Tighe, M.D., FACC, FACP, FASE Cardiovascular Medicine University of Massachusetts Medical School Worcester, MA www.asecho.org 1 Nishimura
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More informationA Practical Approach to Prosthetic Valves
A Practical Approach to Prosthetic Valves Bonita Anderson DMU (Cardiac), MApplSc (Med Ultrasound), ACS, AMS, FASE https://doi.org/10.1161/circulationaha.108.778886 Disclosures None 1 Know the Product Know
More informationTAVR Cases. Disclosures 2/17/2018. February 17, :15 3:30 PM 15 min
31 st Annual State of the Art Echocardiography San Diego, CA February 17, 2018 3:15 3:30 PM 15 min TAVR Cases Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate Professor
More informationTAVR TTE INTERROGATION BY ALAN MATTHEWS
TAVR TTE INTERROGATION BY ALAN MATTHEWS KEYS TO ACCURATE ASSESSMENT EDWARDS SAPIEN VALVE 3 PHASES OF TAVR TTE Evaluation (Qualifying) Placement (Intraoperative) Follow-up (Post-Op) GOALS High quality TTE
More informationResults of Transfemoral Transcatheter Aortic Valve Implantation
Results of Transfemoral Transcatheter Aortic Valve Implantation Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationHemodynamic Assessment. Assessment of Systolic Function Doppler Hemodynamics
Hemodynamic Assessment Matt M. Umland, RDCS, FASE Aurora Medical Group Milwaukee, WI Assessment of Systolic Function Doppler Hemodynamics Stroke Volume Cardiac Output Cardiac Index Tei Index/Index of myocardial
More informationWhen Does 3D Echo Make A Difference?
When Does 3D Echo Make A Difference? Wendy Tsang, MD, SM Assistant Professor, University of Toronto Toronto General Hospital, University Health Network 1 Practical Applications of 3D Echocardiography Recommended
More informationAdopted by Council March 2006, Revised March 2012, September 2015
Guidelines, Policies and Statements E4 Education Protocol: Competences Required Of Cardiac Sonographers Who Practice Adult Transthoracic Cardiac Ultrasound Examinations Adopted by Council March 2006, Revised
More informationEchocardiography. Guidelines for Valve and Chamber Quantification. In partnership with
Echocardiography Guidelines for Valve and Chamber Quantification In partnership with Explanatory note & references These guidelines have been developed by the Education Committee of the British Society
More informationIs TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry
Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry E Van Belle, E Teiger, F Juthier, A Vincentelli, B Iung, H Eltchaninoff, J Fajadet,
More informationHemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves
Hemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves Speaker's name: I have the following potential conflicts of interest to report: Proctorship for Medtronic Agenda Failure modes
More informationFirst Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always
ISPUB.COM The Internet Journal of Cardiology Volume 9 Number 2 First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not T D, J P. Citation T D, J P.. First Transfemoral
More informationA patient with aortic stenosis and LV dysfunction EuroECHO & Other Imaging Modalities 2012 Athens, Greece
A patient with aortic stenosis and LV dysfunction EuroECHO & Other Imaging Modalities 2012 Athens, Greece Jean-Luc MONIN, MD, PhD. University Hospital, Créteil, FRANCE My disclosures: Lecture and/ or consulting
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Transcatheter Aortic Valve Implantation for Aortic Stenosis Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Transcatheter Aortic Valve Implantation
More informationHOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?
HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? John D. Carroll, MD Professor, Director of Interventional Cardiology and Co-Medical Director of the Cardiac and Vascular Center, University of Colorado
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationAffecting the elderly Requiring new approaches. Echocardiographic Evaluation of Hemodynamic Severity. Increasing prevalence Mostly degenerative
Echocardiographic Evaluation of Hemodynamic Severity Steven J. Lester MD, FACC, FRCP(C), FASE Mayo Clinic, Arizona Relevant Financial Relationship(s) None Off Label Usage None A re-emerging public-health
More informationTranscatheter aortic valve replacement with the SAPIEN 3 valve: preparing the field for the final expansion
Editorial Transcatheter aortic valve replacement with the SAPIEN 3 valve: preparing the field for the final expansion Jean-Michel Paradis, Josep Rodés-Cabau Quebec Heart & Lung Institute, Quebec City,
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co-Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationAortic stenosis (AS) remains the most common
Sapien Valve: Past, Present, and Future A look at how the Sapien family of valves continues to evolve to treat a range of patients seeking transcatheter aortic valve replacement. BY RAVINDER SINGH RAO,
More informationMeasuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France
Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France Faculty disclosure Bernard Iung I disclose the following financial relationships: Consultant
More informationIs TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?
Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Didier TCHETCHE, MD. Clinique PASTEUR, Toulouse, France, Conflicts of interest: -Consultant for Edwards LifeSciences
More informationAortic Stenosis: Open vs TAVR vs Nothing
Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More informationSTRUCTURAL. aortic stenosis, transcatheter aortic valve replacement
Received: 4 April 2018 Revised: 17 August 2018 Accepted: 20 August 2018 DOI: 10.1111/joic.12561 STRUCTURAL Outcomes after transcatheter aortic valve replacement in patients with low versus high gradient
More informationCorrado Tamburino, MD, PhD
Paravalvular leak: acceptable or not Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular Department, Director Cardiology Division,
More information